drugset / Trial / NCT02706015
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen and sixty five years old. The first Half of participants will receive Cefaliv®, the other half will receive Neosaldina®.
Timeline
- Start
- 2020-10
- Primary completion
- 2021-05
- Completion
- 2021-07
Outcome
Outcome not reported
Stopped (Business): “Strategic reasons of the company”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dihydroergotamine | Small molecule | — | Oral |
| Comparator | isometheptene | Small molecule | — | Oral |
| Background | Caffeine | Small molecule | — | Oral |
| Background | dipyrone | Unknown | — | Oral |